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As the usual regulatory framework did not fit well during the last Ebola outbreak, innovative thinking still needed. In the
absence of an outbreak, randomised controlled trials of clinical efficacy in humans cannot be done, while during an outbreak
such trials will continue to face significant practical, philosophical, and ethical challenges. This article argues that researchers
should also test the safety and effectiveness of novel vaccines in wild apes by employing a pluralistic approach to evidence.
There are three reasons to test vaccines in wild populations of apes: i) protect apes; ii) reduce Ebola transmission from wild
animals to humans; and iii) accelerate vaccine development and licensing for humans. Data obtained from studies of vaccines
among wild apes and chimpanzees may even be considered sufficient for licensing new vaccines for humans. This strategy
will serve to benefit both wild apes and humans.
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The largest ever outbreak of Ebola in humans was
declared over in spring 2016. But although it disap-
peared from newspapers’ headlines, Ebola has not been
eliminated. Indeed, there continue to be regular out-
breaks in Democratic Republic of Congo in Spring 2017,
and we are currently in the midst of another which
started only a week after the last was declared over in
May 2018 (Centers for Disease Control and Prevention
2018). Ebola continues to circulate in nonhuman animal
(hereafter “animal”) populations, posing a grave risk to
wild animals as well as humans (Olival et al. 2017).
Nonhuman animals constitute a key vector of the virus’s
transmission to humans.
Recognizing that Ebola poses a common threat to
humans and animals, we advocate for a response to
Ebola rooted in a One Health approach to infectious dis-
ease prevention and control. One Health recognizes that
human, animal, and environmental health are inter-
dependent, acknowledges shared disease risks between
humans and animals that occupy the same environ-
ments, and seeks to regulate the human–animal–environ-
ment interactions that contribute to infectious disease
emergence and expression (Degeling et al. 2015;
Landford and Nunn 2012). It moves us away from an
anthropocentric approach to public health—one that
puts humans’ health at the center of public health cam-
paigns—and toward an ecological approach—one that
looks to control or mitigate common threats to organ-
isms within shared environments through innovative
and integrative measures. While the global health com-
munity is justifiably concerned about preventing Ebola
in humans, it would be wise to consider ways of pre-
venting Ebola in animals, too, thereby interrupting pre-
dictable chains of transmission of Ebola from animals to
humans (and vice versa). Furthermore, conservationists
are rightly concerned about Ebola’s effect on apes, as
populations of wild apes have, in recent years, substan-
tially diminished due to Ebola outbreaks. Preventing
Ebola in wild apes, in other words, also protects apes
from endangerment and extinction.
This means there is an urgent need for researchers to
assess what we already know about Ebola, and to think
about innovative, integrative approaches to Ebola virus pre-
vention. An anthropocentric approach to infectious disease
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prevention would prioritize developing an Ebola vaccine
for humans. But this will not work in the case of Ebola
because the usual regulatory framework, which can require
evidence from human studies, taking up to 14years to
complete, does not fit well (Thielman et al. 2016). In the
absence of an outbreak, randomized controlled trials of
clinical efficacy in humans cannot be done, while during a
future outbreak such trials will continue to face significant
practical, philosophical, and ethical challenges associated
with limiting access to new medicines to the research con-
text when there is an immediate widespread public health
crisis (Edwards 2013).
We argue that in relation to vaccination, researchers
should also test the safety and effectiveness of novel vac-
cines in wild apes, employing a One Health approach to
public health and a “pluralistic” approach to evidence.
There are three reasons to test vaccines in wild popula-
tions of apes: (i) reduce interspecies Ebola transmission;
(ii) protect apes; and (iii) accelerate vaccine development
and licensing for humans. Data to help validate surrogate
outcomes in humans obtained from studies of vaccines
among wild apes and chimpanzees may be considered by
regulators to be desirable and sufficient for licensing new
vaccines for humans ahead of the next outbreak. At the
very least, evidence from trials of new vaccines in wild
animals will contribute to the evidence base for a new
vaccine’s clinical outcomes in humans: safety, efficacy,
and effectiveness. Owing to challenges in mounting large-
scale vaccine trials in humans, pluralism about evidence
is warranted. This strategy will serve to benefit both wild
apes and humans. In this way, we seek to make beneficial
connections between the One Health approach (which
provide opportunities to gather evidence from various
species and sources), on the one hand, and what is known
in philosophy of science as methodological or epistemic
pluralism, on the other hand.
EBOLA VACCINE DEVELOPMENT SO FAR
Though several are in development, there is still no
licensed Ebola vaccine. There simply are not many
opportunities to pursue vaccine trials in the real world
because large outbreaks in humans, thankfully, do not
occur very often. Testing the safety and effectiveness of
a new vaccine typically involves a randomized con-
trolled trial (RCT), in which many thousands of people
who are at risk of exposure to the disease are vaccinated
and compared to controls. The impossibility of predict-
ing when the next outbreak will occur, and in which
geographic areas, presents a practical challenge to testing
candidate vaccines in human subjects.
The Ebola outbreak of 2014–2016 provided an oppor-
tunity to test the safety and effectiveness of promising
vaccines, as well as treatments, while thousands of peo-
ple were at risk of exposure to the devastating illness.
However, the outbreak also saw the international com-
munity struggle with questions of research methodology
to test the novel agents’ safety and effectiveness (Calain
2016). In the context of having no standard medical treat-
ments available and of having several candidate medi-
cines only just becoming ready to “test” in humans for
the first time, questions surrounded how to amass safety
and effectiveness evidence about novel therapeutics and
vaccines. Some argued that an RCT ought to be per-
formed in order to produce the most reliable evidence
base (Rid and Emanuel 2014). Others advocated the use
of “alternative” trials that, for example, do not random-
ize research subjects to a placebo arm on the basis that
randomization to a placebo arm was unethical because
of high mortality and morbidity associated with illness
(Adebamowo et al. 2014; Caplan et al. 2015; Edwards
2013). Research groups that began trials during the out-
break ultimately abandoned them, in part due to under-
enrollment as the outbreak waned (Gates 2015).
Concerns about the incompatibilities in the methods
favored by different stakeholders are likely to complicate
effectiveness research in humans either before or during
any future outbreak.
Two experimental vaccines show promise in humans:
Merck’s vaccine and Janssen’s vaccine. Merck and
Janssen have both undertaken trials with human sub-
jects, although neither has provided sufficient evidence
for licensing. Merck has patient outcomes data for rVSV-
ZEBOV live vaccine. With Emergency Use Authorization
by the World Health Organization (WHO), it adminis-
tered the experimental vaccine to nearly 800 people
within 1 week in 2016, including 182 who were consid-
ered to be high-risk contacts, to contain a flare-up of
Ebola in March 2016 as the outbreak waned (World
Health Organization 2016). Merck introduced an add-
itional arm of its vaccine with a booster, which is not
always possible to administer in the field. A follow-up
phase 3 trial of the rVSV vaccine adopted a “ring”
design, which was declared a success in terms of pre-
venting disease transmission. A ring design seeks to treat
only those in close contact with a cluster of known
cases, thereby forming a “ring” of protection around an
outbreak. Nonetheless, the FDA did not find the data
compelling enough to fully license the vaccine (Henao-
Restrepo et al. 2017). Merck’s still-experimental vaccine
is currently being used in DRC but not always adhering
closely to the ring method due to the difficult social con-
ditions in the region.
Janssen’s vaccine was deployed in a trial toward the
end of the 2014/16 outbreak and yielded data on
immunogenicity alone—an evidential facet that makes
some regulatory bodies cautious. Immunogenicity tests
the body’s ability to mount an immune response, but
does not necessarily mean that one is immune to the dis-
ease in question. Thus, data on a vaccine’s immunogen-
icity does not entail that the vaccine in question prevents
illness. A large comparative trial in humans (PREVAC),
led by the Partnership for Research on Ebola Vaccination,
is now recruiting and will use immunogenicity as a
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surrogate endpoint for effectiveness in the absence of a
human outbreak (National Institute of Allergy and
Infectious Disease [NIAID] 2017). Currently, any market-
ing license would need to appeal to data validating
immunogenicity data with clinical outcomes but only in
nonhuman animal studies. While each vaccine will be
compared with a placebo control, the hope is that recruit-
ment rates will be high enough to allow a head-to-head
comparison between them. Given pragmatic constraints
associated with severity of the situation on the ground
(e.g., refrigeration required for certain drugs), evidence of
effectiveness—not efficacy—has more value for medical
practitioners, who need multiple tools as they face mul-
tiple tasks and multiple impediments. Drug companies
naturally wish to be the lead market provider on the basis
of evidence of superiority, but for public health agencies
and doctors, multiple treatments are a better resource for
treating populations, especially when so much is
still unknown.
Noticeably absent from the list of candidate treat-
ments and vaccines reviewed by WHO during the
2014–2016 human outbreak was a vaccine developed by
Peter Walsh purely for the purposes of conservation of
chimpanzees (Walsh et al. 2017). The orally delivered
vaccine was made up of the live, weakened rabies virus,
with an added gene for the main surface glycoprotein
from the Ebola virus. Walsh had promising preliminary
data from a trial of the vaccine’s safety and effectiveness
using 10 captive chimpanzees at an animal facility in
Louisiana. In 2015, however, the trial was cut short
when amendments to the U.S. Endangered Species Act
banned the use of chimpanzees in medical research. The
law, which came into effect in 2016, places captive chim-
panzees on the endangered species list, effectively ban-
ning invasive research using them.
Ebola is extremely difficult to model in other animals,
and this presents another practical barrier to vaccine
development. Mice, hamsters, and guinea pigs have all
been developed as animal models of infection for a num-
ber of species and strains of Ebola virus and Marburg
virus. Yet (as with most research on animal models) these
rodent studies alone are insufficient to reliably guide
human vaccine development, as they do not exhibit the
symptoms of disease present in the typical human case of
Ebola—that is, abrupt onset with flu-like symptoms,
including fever, malaise, and myalgia, followed by ano-
rexia, lethargy, nausea, vomiting, and diarrhea.
Hemorrhaging can develop, particularly in severe cases at
the peak of illness, and include petechiae, uncontrolled
bleeding from venipuncture sites, epistaxis, and other
mucosal hemorrhages. Fatal cases are accompanied by
hypovolemic shock and multiple organ failure.
As nearly all aspects of filovirus infection in humans
are replicated in rhesus macaques and other primates,
some have concluded that nonhuman primates are the
most valuable animal model of human disease (Shurtleff
and Bavari 2015). Several nonhuman primate species
have been used to model human Ebola infection, includ-
ing African green monkeys, marmosets, baboons, cyno-
molgus macaques, and rhesus macaques (Nakayama and
Saijo 2013). There are some notable limitations, but none-
theless, the features of disease in both cynomolgus and
rhesus macaques appear to best model, in the laboratory,
the progression of Ebola disease in humans.
As stated, the confluence of several factors compli-
cate Ebola vaccine development. Primates provide an
opportunity to model and study Ebola virus in the lab
setting; however, some primates are banned from inva-
sive research, and animal welfare concerns should give
us pause when it comes to using nonbanned primates
(Barnhill et al. 2016). Alternative evidence bases of new
vaccines’ safety and effectiveness are sorely needed to
guard against another outbreak, as is an approach to
handle different evidence types in more resourceful and
beneficial ways. This need motivates our call for expand-
ing vaccine research to include study of wild apes and
chimpanzees that are at risk of exposure to Ebola virus.
Three further moral reasons for doing so are reviewed in
what follows.
Reducing Interspecies Ebola Transmission
A One Health approach to controlling infectious disease
emphasizes that animal health and human health are
intimately intertwined, and this is especially the case for
Ebola virus. As humans infringe upon animals’ natural
habitats through urban sprawl, deforestation, tourism,
need for new food sources, and anthropogenic climate
change, humans and animals increasingly encounter
each other. They increasingly share not only spaces, but
also diseases.
As noted in the preceding, wild gorillas and chim-
panzees in central Africa have experienced occasional
Ebola outbreaks. Yet like their human counterparts, they
are too ravaged by the virus to serve as its host over the
long term. Experts say that a nonprimate reservoir spe-
cies is likely to harbor the virus only at low levels, and
without becoming sick (Groseth et al. 2007; Saez et al.
2015). Animals ranging from rodents to livestock to
domestic dogs and cats may not be victims of Ebola, but
they could contribute to transmission to humans and
apes. It is thought that Ebola spreads from apes to
humans when a hunter kills and eats an animal, or
when someone meets an infected ape corpse (Whitfield
2003). Recognizing the ways in which the Ebola virus
lives and circulates within shared environments is crit-
ical to control and mitigation efforts.
Since the disease first emerged in Zaire, now
Democratic Republic of the Congo, 40 years ago, efforts
to trace the exact nonhuman origins of human outbreaks,
including the most recent one, have been inconclusive.
What is clear, however, is that mass animal deaths act as
an early warning system for human outbreaks (Funk
and Piot 2014). Researchers are now modeling past
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outbreaks for common ecological and environmental fac-
tors, such as vegetation, elevation, and the presence of
suspected reservoir species such as fruit bats and insect-
eating bats, and carriers such as apes, to create a map
showing high risk of human transmission (Bisson et al.
2015; Redding et al. 2016). By intervening in either the
vector animals, like apes and chimpanzees, or reservoir
species, like bats and rodents, the risks to human health
might be reduced.
Developing an Ebola vaccine that is safe and effective
for both nonhuman primates and human primates inter-
venes in a known vector of Ebola and achieves the
vision of “inter-species herd immunity,” as recently pro-
posed by Capps and Lederman (2015). Herd immunity
refers to resistance to infectious diseases within a popu-
lation that results from having a sufficiently high pro-
portion of individuals immune to the disease through
vaccination. When herd immunity is achieved, even
unvaccinated individuals are protected. Interspecies herd
immunity would be agnostic as to which animals—
human or otherwise—are vaccinated. The important goal
would be achieve population-level resistance to the
Ebola virus. Reliance on developing “model organisms”
of Ebola, which attempt to replicate human disease in
animals, represents an unfortunately partitioned view of
the intimate connections between human and animal
health. Animals are not merely models of Ebola; they are
victims. In these cases, humans and apes share a com-
mon disease threat against which multifaceted and inte-
grated vaccine research might be marshaled (Capps and
Lederman 2015; Olival et al. 2017; Reed et al. 2014).
Protecting Wild Apes and Chimpanzees
Several studies have tracked the impact of Ebola on wild
apes, gorilla, and chimpanzee populations (Barmejo,
2006; Caillaud et al. 2006; Genton et al. 2017; Pilcher
2004; Ryan and Walsh 2011; Walsh et al. 2003). As early
as 2003, Walsh and colleagues referred to an “ape Ebola
epidemic,” calling it “a major conservation crisis” (2003,
613). Bermejo et al. (2006) studied wild gorillas for more
than a decade at a gorilla sanctuary near the
Gabon–Congo border and found that between 2002 and
2003, Ebola killed more than 5000 gorillas in their study
area, with gorilla mortality rates between 90 and 95%.
Not to be overlooked, they also estimate that the chim-
panzee population in the same area and time period
declined by 89% (Pilcher 2004). The authors conclude:
“We hope this study dispels any lingering doubts that
[Ebola virus] has caused massive gorilla die-offs.”
What’s more, Caillaud et al. (2006) tracked gorillas in a
different study area in the Democratic Republic of
Congo, reporting that between December 2003 and July
2004, 95% of gorillas in their study area died from the
disease. Data from these gorilla studies led the
International Union for Conservation of Nature (IUCN)
to classify the species as “critically endangered” in 2008.
Ebola therefore represents a threat to wild ape and
chimpanzee populations, and this fact supports an
urgent argument from conservation of the species for
developing Ebola vaccines suitable for use in apes and
chimpanzees (Ryan and Walsh 2011). All the early work
by Walsh on captive chimpanzees was intended to bene-
fit the conservation effort with no ambition for applica-
tion in humans.
Humans have exacerbated the threat Ebola poses to
wild apes and chimpanzees through deforestation, urban
sprawl, tourism, and other means. We would be remiss
not to point that chimpanzees’ and apes’ health also
depends on humans’ activities. Humans structure their
environments, intentionally or unintentionally. It is
incumbent upon us to create shared environments that
also promote the health and well-being of other animals.
Vaccination is certainly not the only way to promote the
health of wild apes, gorillas, or chimpanzees that share
our planet, but it may be one way.
Accelerating Vaccine Development in Humans
Morbidity data show that great apes and chimpanzees
experience a disease trajectory very similar to that of
humans. Thus, it is reasonable think that vaccine safety
and effectiveness data obtained from wild great ape or
chimpanzee populations might inform vaccine develop-
ment in humans. Biologically, immunologically, pharma-
cokinetically, and otherwise, apes and chimpanzees and
humans are remarkably similar. Put another way, the
“translational distance” between apes and humans is
very short (Kimmelman 2010). Data from wild ape and
chimpanzee populations may provide evidence of the
vaccine’s safety and effectiveness in humans, and may
even contribute to a regulatory license for an Ebola vac-
cine for humans ahead of the next outbreak, depending
on the type of evidence sought and how it is assessed
alongside data from humans.
Stressing the benefits to humans that might result from
vaccination trials in wild apes and chimpanzees does not
undermine our commitment to a One Health approach to
public health. On the contrary, protecting humans from
shared threats is also part of the complex puzzle of creating
environments and ecosystems that are more resilient to
infectious diseases. Vaccinating humans is likely be essen-
tial to achieving interspecies herd immunity.
Questions remain about what sort of evidence would
be regarded as sufficient to gain a full market license and
when that evidence could practically and ethically be
sought. In terms of both speed and effectiveness, RCTs
are still awarded a privileged status when methods of col-
lecting evidence are considered during an outbreak (U.S.
National Academies 2017). For half a century or so, RCTs
have been thought to provide evidence with the fewest
biases so had become the “gold standard.” By the time
the candidate treatments were ready for human use dur-
ing the 2014–2016 outbreak, there were epidemiological
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data emerging from the field that showed variation in the
accumulating case facility rates from 50% to 80% between
individuals and between reporting treatment centers
(mainly facilities run by Medicins Sans Frontieres), such
as they were early on. On this basis, the Food and Drug
Administration (FDA) concluded that sound science
required a concurrent control (of best available supportive
care) to reduce an anticipated bias associated with using
historic controls (Cox et al. 2014). Variation between cen-
ters, the FDA argued, also ruled out randomized trials at
the cluster level, including any step-wedge approach
(which allocates new clusters to the intervention sequen-
tially until all clusters receive the intervention).
Establishing efficient statistical associations between treat-
ment and clinical effect was the FDA’s primary concern.
However, variation in outcomes might suggest the exist-
ence of subpopulations that are not yet well understood—
notably pregnant women—which could be disguised by
aggregated data. Thus, their results could be ambiguous
and misleading, while there is significant and unidentified
heterogeneity between subpopulations. Radically different
methods for designing clinical trials were ultimately used
during the human outbreak of 2014–2016, but mainly due
to pressure from past colonial partners and for different
reasons, with mixed and inconclusive results (Gates 2015).
Strikingly, where RCTs are not feasible (as in cases
of rare disease) or are unethical to carry out (as in Ebola
exposure studies involving healthy humans), the FDA
has been willing to license new drugs and vaccines
based on other types of evidence. For example, where
clinical effectiveness studies would require deliberately
exposing humans to potentially lethal pathogens, the
Animal Rule permits the FDA to license a new drug
based on effectiveness data from animals alone—that is,
without any clinical trials in humans (Edwards 2015).
Even if data from wild ape and chimpanzee trials
were not sufficient for licensing a new vaccine, at the
very least, evidence from other sources such as ape and
chimpanzee studies (and using multiple methods) would
contribute to the evidence base for the three vaccines
(and others) currently in development, and would guide
global health experts in their decision about whether,
when, and how to mount trials in humans. Indeed, evi-
dence specifically from wild apes and chimpanzees
could help reevaluate the perceived scientific need for
RCTs in humans during the next outbreak. In this way,
an overall causal picture could be better formed by the
beginning of the next outbreak in humans, and later
completed by considering observational or pragmatic tri-
als in humans alongside evidence of mechanisms gath-
ered via laboratory studies. Finally, studies in wild apes
might clarify how immunogenicity measures change
clinical outcomes in humans. Outcomes in great apes
potentially contribute to alleviating uncertainty more
than evidence gleaned from rodent studies, or laboratory
studies of cynomolgus and rhesus macaques.
Far from being problematic, in the longer run, mul-
tiple methods for gathering clinical evidence of the
effects of novel vaccines could provide more robust sci-
entific inferences regarding causal relationships.
Unreflective reliance on clinical effects observed from
large RCTs is beginning to wane (Bothwell et al. 2016).
Those who are charged with coordinating research in the
context of a public health crisis should do it with an eye
to the possibility of bringing it all together. Given the
plurality of evidence available, Ebola deserves an equally
pluralistic approach to how we analyze and assess the
suitability of new vaccines under regulatory approval.
PLURALISM: IS IT FEASIBLE?
A One Health approach to public health, and the three
specific reasons reviewed, motivate our argument for
mounting vaccine studies in wild apes and chimpanzees
already at risk of Ebola exposure in the absence of
another human outbreak. These trials would stand to
benefit both wild populations of animals under threat of
endangerment from Ebola outbreaks, and humans, who
also suffer greatly and may die from the disease.
One might read our call for increased research
involving apes and chimpanzees as a return to a dark
time of biomedical research involving healthy captive
primates in the laboratory, before protections of chim-
panzees and great apes from research went into effect.
But that is not our suggestion. A more pragmatic and
arguably more ethical approach is to identify certain
groups in the wild and adopt the testing methods for
conservation purposes as already planned by Walsh
et al. (2017) and refined subsequently by others
(Willyard 2017). Testing vaccines’ effectiveness against a
naturally occurring Ebola challenge (within geographic-
ally contained environments) rather than sacrificing
healthy apes in the laboratory is more consistent with
the accepted ethical approach to both animal and human
experimentation. Moreover, the current trial of two vac-
cines in humans (PREVAC) could be compared and com-
bined with data from wild apes.
Walsh and others have already proposed an experi-
mental design in the wild but only for conservation pur-
poses. In 2013, Walsh’s short-lived studies involving
captive chimpanzees had shown some immunogenicity
without adverse side effects, and he had long planned to
pursue conservation work in wild chimpanzees and
gorillas endangered by the Ebola virus (Walsh et al.
2017). In an overview of what those trials might look
like, he proposed oral vaccination delivery in response
to the challenges of traditional hypodermic dart methods
of inoculation. The densities of forests in which gorillas
and chimpanzees live often make it difficult to track and
inoculate them in the wild. The promise of noninvasive,
oral vaccinations is not only practical, but also induces
less stress for the animal. Stress can be known to trigger
a strong immunosuppressant reaction, thus hindering
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the effectiveness of the drug post inoculation. A live-
virus Ebola vaccine might be preferable because it can
be eaten, unlike killed-virus vaccines, which require
injection through targeted darts. Walsh also designed the
trial using a dispenser from which apes could get sweet
vaccine-laced treats, monitored by a camera recording
those who took some. The effectiveness of the vaccine
could then be tested by measuring antibodies in the
apes’ excretions. The conservation work was seemingly
abandoned but is worth resurrecting, especially in light
of the growing public health threat to, and from, wild
animals with Ebola.
It is important to note that research with wild ani-
mals that is aimed to benefit the animals is exempt from
U.S. protections of great apes and chimpanzees. An
exception to the U.S. Endangered Species Act is made
for research that benefits chimpanzees in the wild or
aids in the chimpanzees’ propagation or survival, includ-
ing work to improve chimpanzees’ habitats or manage-
ment of wild populations. Researchers seeking to use
chimpanzees for allowed purposes must apply for an
exemption. While this process can be time-consuming,
the exception would seem to allow for vaccine trials like
the one Walsh proposed.
Some have noted that it might be necessary to use
captive primates to obtain safety and immunogenicity
data on vaccines in development, ahead of deploying the
experimental vaccine in a field test on primates as
allowed by the U.S. exemption (Capps and Lederman
2015). However, it is worth noting that immunogenicity
data could also be obtained from human subjects, as in
the trial currently underway. Evidence of mechanisms as
an auxiliary type of evidence, such as pharmacokinetic
data, might be obtained from other animals (e.g., mice or
rodents), and while a model organism is not necessary.
Notwithstanding, studies of vaccines in wild apes and
chimpanzees need not entail increased use of apes and
chimpanzees in a laboratory setting prior to the field
tests, if, say, prior data in humans show that they are
safe and potentially beneficial to conservation efforts.
Humans would be treated as models for studying the
drug’s effects in primates, flipping the way biomedical
researchers typically think about the relationship
between animal and human subjects of research.
CHALLENGES TO THE NATURAL EXPERIMENT
Use of vaccination in the wild is already controversial,
so the prospect of testing unproven vaccines in the wild
needs careful thought (Osofsky et al. 2016; Walsh et al.
2017; Willyard 2017). For example, the tragic case of
invasive research (specifically handling-induced stress)
on a population of Serengeti-Mara wild dogs still looms
large in the consciousness of conservationists (De Villiers
et al. 1995). Between 1985 and 1991, the entire study
population of endangered wild dogs (Lycaon pictus),
comprising 14 packs of 200 individuals, died in Tanzania
and Kenya where the species had been identified for
intensive conservation efforts. It was never shown
exactly what caused the dogs to die, but the work was
very invasive and disruptive for a long period of time,
causing incalculable distress to the animals. However,
there is probably enough evidence on the safety of cur-
rent Ebola vaccines to provide the scientific rationale to
test them in targeted wild populations of apes.
Another concern is the risk of a replicating virus
unleashed in the wild, exacerbated by the use of a live
vaccine. The remote risk of a live vaccine replicating
unhindered in the wild population can be reduced or
even eliminated (Osofsky et al. 2016). Specific wild pop-
ulations could be identified as being at highest risk of
Ebola and vaccines could be further tested to introduce a
“ring” of protection around a known outbreak based on
geography and known and contained territorial reach
(Kucharski et al. 2016; Reed et al. 2014).
The counterarguments to the testing of vaccines in
wild apes and chimpanzees center on exposing the ani-
mals and their ecosystem to harms, perhaps significant
harms. The inability of chimpanzees or great apes to
consent to research places a great responsibility on those
deciding for them to what extent those harms are justi-
fied by benefits. Those decisions ought to be guided by
the expectation of benefit to the wild animals, our ability
to mitigate harms to the animals and to the ecosystem,
and the ability to perform experiments that produce reli-
able data and knowledge about the vaccines’
effectiveness.
While there are major issues concerning the way to
balance risks and expected benefits to individual animals
for the pursuit of aggregate benefit to the particular spe-
cies, we are here interested in increasing the aggregate
benefit across species through cross-species vaccination
and perhaps even achieving interspecies herd immunity.
Difficult questions about balancing risks and benefits
remain, for example, about quantifying risks and benefits
of research across species, and about balancing risks and
expected benefits to individual animal subjects of
research versus risks and expected benefits at the species
or population level. Such tensions are inevitable within a
One Health approach, and more research is needed to
understand these tensions and ethically balance risks
and benefits both across and within species (Rock and
Degeling 2015).
CONCLUSION: A NEW ERA OF
PLURALISTIC EVIDENCE
We are currently faced with a stark choice during an
outbreak: deploy only the Merck vaccine and gather
observational data on clinical effectiveness, test on
imperfect animal models in laboratory “challenge” stud-
ies, or perform mutually beneficial work in great apes
facing a natural exposure to Ebola. Merck’s vaccine was
awarded a breakthrough therapy designation by the
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FDA, and was put on a fast track to licensure as more
data accumulate. Considering data from studies with
chimpanzees and great apes in the wild might aid and
accelerate this process, perhaps removing the need for
future RCTs during another outbreak. The impact on
wild nonhuman primate populations is likely
much worse.
Testing promising treatments and vaccines in chim-
panzees and great apes is a prudent and justified next
step in the development of Ebola virus vaccines. While it
is not guaranteed that the FDA will embrace a more
methodologically pluralistic approach to evidence, it is
already open to the concept of adaptive licensing and
has adopted the Animal Rule when evidence of clinical
outcomes cannot be gained in particular, so it is already
somewhat sensitive to context. In the meantime, a vac-
cine trial or treatment trial (if necessary) in wild popula-
tions would not only benefit the wild population, but
also promote human, animal, and ecological health by
identifying promising, if not already licensable, Ebola
vaccines and treatments. More research is necessary to
identify feasible and ethical approaches to experimenting
on wild populations of chimpanzees and great apes, and
Dr. Walsh’s study design is a start. The ethical case,
however, is already strong.
The current situation of Ebola vaccine research may
seem somewhat unique, yet opportunities to gather spe-
cific evidence from our nearest living primate relatives
under a One Health approach (which cannot be gained
from humans) are nonetheless worth debating. That said,
a more flexible approach to regulation of new drugs in
humans generally may serve to provide more robust evi-
dence by accepting data from other sources and at differ-
ent stages of the development process. This may be
especially important with the rise of zoonotic diseases.
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